LSTA logo

LSTA Lisata Therapeutics, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$1.21
-0.07 (-5.47%)

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II…

Market Cap: $10.90Mwww.lisata.com

Price

No data yet.

Social Signal Score

43
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
37
3 mentions
—
90d
36
6 mentions
—
news: 6

Analyst Ratings

2 analysts
Holdconsensus
Strong Buy 0Buy 0Hold 2Sell 0Strong Sell 0

Revenue

$0.00-100.00%
$0.00$3.39M$6.78M$10.18M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-2.33
$-2.33–$-2.33
1 analysts
FY2026
$-1.09
$-1.09–$-1.09
1 analysts
FY2027
$-1.16
$-1.16–$-1.16
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
David J. Mazzo
Sector
Healthcare
Industry
Biotechnology
Employees
21
Beta
0.80
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-0.75
www.lisata.com